Related content

Prolonged treatment with three-weekly docetaxel plus daily prednisolone for metastatic castration-resistant prostate cancer: a multicenter, phase II, open-label, non-comparative, extension study in Japan

By Nishimura Kazuo  

International Journal of Clinical Oncology, Vol. 18, Iss. 2, 2013-04 ,pp. : 306-313

Springer Publishing Company

Access to resources Recommend Favorite

A phase II study of the antisense oligonucleotide GTI-2040 plus docetaxel and prednisone as first-line treatment in castration-resistant prostate cancer

By Sridhar Srikala   Canil Christina   Chi Kim   Hotte Sebastien   Ernst Scott   Wang Lisa   Chen Eric   Juhasz Agnes   Yen Yun   Murray Peter   Zwiebel James   Moore Malcolm  

Cancer Chemotherapy and Pharmacology, Vol. 67, Iss. 4, 2011-04 ,pp. : 927-933

Springer Publishing Company

Access to resources Recommend Favorite

Carboplatin-etoposide combination chemotherapy in metastatic castration-resistant prostate cancer: A retrospective study

By                      

Molecular and Clinical Oncology, Vol. 3, Iss. 6, 2015-01 ,pp. : 1208-1212

Science Publishers

Access to resources Recommend Favorite

Docetaxel in combination with estramustine and prednisolone for castration-resistant prostate cancer

By Kuramoto Tomomi   Inagaki Takeshi   Fujii Reona   Sasaki Yumiko   Nishizawa Satoshi   Nanpo Yoshihito   Matusmura Nagahide   Kohjimoto Yasuo   Hara Isao  

International Journal of Clinical Oncology, Vol. 18, Iss. 5, 2013-10 ,pp. : 890-897

Springer Publishing Company

Access to resources Recommend Favorite

Phase I dose-escalation and pharmacokinetic study (TED 11576) of cabazitaxel in Japanese patients with castration-resistant prostate cancer

By Mukai Hirofumi   Takahashi Shunji   Nozawa Masahiro   Onozawa Yusuke   Miyazaki Jun   Ohno Keiji   Suzuki Kazuhiro  

Cancer Chemotherapy and Pharmacology, Vol. 73, Iss. 4, 2014-04 ,pp. : 703-710

Springer Publishing Company

Access to resources Recommend Favorite